Table of Contents
- Medical Disclaimer:
- Overview
- Pathophysiology of Spasticity
- The Science: The Endocannabinoid System and Motor Modulation
- Clinical Research: Clinical Evidence for Spasticity
- Alabama Regulations: The Homestead Health Standard
- How to Qualify in Alabama for a Medical Cannabis for Spasticity
- About Homestead Health
- Alabama Residents Living With ALS, MS, and Spinal Cord Injuries Also Ask
- Article References
- Additional Reading
Medical Disclaimer:
Homestead Health is a licensed medical cannabis processor and does not make medical claims. The information provided is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. All persons must speak to a licensed, state-registered physician to be diagnosed and/or recommended medical cannabis for a qualifying medical condition in the state of alabama.
By Homestead Health – Alabama’s Leader in Pharmaceutical-Grade Medical Cannabis Processing
Overview
Spasticity remains a highly prevalent and disabling symptom for Alabamians living with Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and spinal cord injuries (SCI). In Alabama, approximately 410 individuals are estimated to be living with ALS, a condition so impactful that the state legislature designated May 2026 as ALS Awareness Month [4]. Furthermore, more than half of MS patients suffer from spasticity during the course of their illness, often leading to significant reductions in mobility and quality of life [2]. Recognizing these challenges, the Alabama Medical Cannabis Commission (AMCC) has approved medical cannabis to treat spasticity associated with these specific neurological conditions [3].
Pathophysiology of Spasticity
Spasticity is characterized by involuntary muscle stiffness and spasms resulting from damage to the motor neurons within the Central Nervous System (CNS) [1]. The underlying mechanisms vary by condition:
- Multiple Sclerosis (MS): Immune-mediated destruction of the myelin sheath disrupts nerve signaling, causing “short circuits” in motor pathways [2].
- Amyotrophic Lateral Sclerosis (ALS): The progressive degeneration and loss of motor neurons in the brain and spinal cord lead to muscle rigidity and eventually atrophy [4].
- Spinal Cord Injury (SCI): Damage results in a disconnection between the brain and the spinal cord’s reflex arcs, leading to exaggerated muscle contractions [1].
The Science: The Endocannabinoid System and Motor Modulation
The Endocannabinoid System (ECS) serves as a ubiquitous modulator of neurotransmission, maintaining a delicate balance in the brain and spinal cord [1].
- Motor Control Receptors: CB1 and CB2 receptors are found in the spinal cord, basal ganglia, and cerebellum—regions responsible for coordinating movement. Activation of these receptors can dampen the over-firing of motor neurons, thereby reducing tremors and spasticity [1, 2].
- Neuroprotective Mechanisms: During neurological insult, the body often increases endocannabinoid concentrations as a protective response. Clinical research suggests that supplementing these levels with exogenous cannabinoids can ameliorate spasticity and protect neurons from further excitotoxic damage [1].
- Targeting the Nervous System: For SCI patients, cannabinoids interact with receptors in both the central and enteric nervous systems to alleviate muscle tension and reduce the frequency of painful nocturnal spasms [1, 6].
Clinical Research: Clinical Evidence for Spasticity
Multiple Sclerosis
Oral cannabis extracts are classified as “effective” for reducing patient-reported spasticity symptoms. [1, 2]
Spasticity Relief
Systematic reviews show a significant decrease in muscle stiffness as measured by the Ashworth Scale. [2]
Associated Symptoms
Patients report secondary relief from spasm-related pain, tremors, and nocturia (night-time urination). [2]
ALS/Motor Neuron
Cannabinoids are utilized to manage sleep disturbances, anxiety, and end-of-life spasticity. [4, 6]
Alabama Regulations: The Homestead Health Standard
Homestead Health operates under the strict oversight of the Alabama Medical Cannabis Commission (AMCC) to ensure patients receive pharmaceutical-grade medicine that meets the highest safety standards [3, 5].
- Clean Formulation: Under Rule 538-X-6-.04, all products must be processed using Good Manufacturing Practices (GMP). Our formulations contain no additives other than pharmaceutical-grade excipients, ensuring safety for patients with sensitive neurological profiles [5].
- Purity Testing: All medicine undergoes rigorous laboratory testing to verify it is free from pesticides, heavy metals, and microbial contaminants—a critical factor for MS and ALS patients who may have compromised immune systems [5].
- Tamper-Evident Packaging: In accordance with Rule 538-X-6-.05, all products are delivered in child-resistant, tamper-evident containers to prevent accidental ingestion and maintain product integrity [5].
How to Qualify in Alabama for a Medical Cannabis for Spasticity
To qualify for a medical cannabis card in Alabama for ALS, MS, and Spinal Cord Injuries, patients must follow a regulated process [4, 7]:
Dosage Limits: Patients are generally limited to 50 mg of THC daily for the first 90 days. For terminal patients, a physician may increase the dosage beyond 75 mg, though this may impact driving privileges [7].
Medical Diagnosis: A formal diagnosis of ALS, MS, and Spinal Cord Injuries with associated chronic pain, spasticity, and other symptoms
Physician Certification: Consultation with an Alabama physician registered with the Alabama Board of Medical Examiners (ALBME) who has completed the state-mandated training.
Treatment History: Documentation that conventional medical treatments (e.g., standard antiemetics or traditional pain medications) have failed or are contraindicated [4].
About Homestead Health
Homestead Health is more than a processor; we are a partner in the Alabama healthcare community. Our commitment to wellness and healthcare means we prioritize science over trends. We work within the strict bounds of Chapter 538-X-6 to ensure that our facilities meet the highest standards of the Alabama Administrative Code providing high quality, consistent, and laboratory tested medicine for Alabama residents.
Alabama Residents Living With ALS, MS, and Spinal Cord Injuries Also Ask
Yes. Spasticity associated with MS, ALS (or other motor neuron diseases), and spinal cord injuries is an officially recognized qualifying condition in Alabama [3].
Under Rule 540-X-25-.11, the initial maximum daily dose is 50mg of THC. After 90 days of continuous care, a physician may increase this to 75mg. Terminal patients may exceed these limits under specific medical supervision [7].
Yes. Research indicates that cannabinoids provide a dual benefit for neurological patients by reducing both the physical stiffness of spasticity and the neuropathic pain that often accompanies it [2, 6].
Alabama law strictly prohibits “smokeable” products, vapes, and traditional food-based edibles. Instead, patients have access to pharmaceutical forms like capsules, tinctures, and non-sugar-coated peach-flavored gelatinous cuboids [5].
You must provide medical records confirming your diagnosis (ALS, MS, or SCI) and documentation from your physician stating that conventional treatments (such as baclofen or tizanidine) have failed or are contraindicated [3].
Yes. If a physician recommends a daily dose exceeding 75mg for a terminal condition, state law requires they notify the patient that their driver’s license will be suspended for public safety reasons [7].
Patients must visit a physician registered with the Alabama Board of Medical Examiners (ALBME) who has completed the state-mandated training course. A directory is available on the AMCC and ALBME websites [3].
Potential interactions exist, particularly with sedatives or muscle relaxants. It is essential that your certifying physician performs a comprehensive review of your current medication list to prevent adverse effects [1, 2].
As required by Alabama law, all gelatinous products are flavored only in peach. This ensures they are recognized as medicine and to prevent them from being mistaken for candy or traditional edibles [5].
No. Under current state and federal law, health insurance providers and government programs like Medicaid are not required to cover or reimburse the cost of medical cannabis [3].
The following Alabama counties have been authorized as medical cannabis dispensing sites by the AMCC as of April 2026. Each site not only services county residents but also surrounding areas.
Note: A certification from any AMCC-registered physician in Alabama allows you to purchase at any licensed site in the state.
Baldwin County (Daphne)
Calhoun County (Oxford)
Cullman County (Cullman)
Etowah County (Attalla)
Jefferson County (Birmingham)
Limestone County (Athens)
Mobile County (Mobile)
Montgomery County (Montgomery)
Talladega County (Talladega)
Article References
Citations Used For This Article
- Pharmacology & Therapeutics. Cannabinoids and Multiple Sclerosis. https://pubmed.ncbi.nlm.nih.gov/12182963/
- Journal of Personalized Medicine. Efficacy of cannabinoids for controlling MS-related spasticity. https://pmc.ncbi.nlm.nih.gov/articles/PMC11536376/
- Alabama Medical Cannabis Commission (AMCC). Qualifying Conditions. https://amcc.alabama.gov/
- ALS Association / Alabama Legislature. ALS Awareness Month and State Prevalence Data 2026. https://www.als.org/sites/default/files/2025-01/Alabama.pdf
- Alabama Administrative Code. Chapter 538-X-6: Regulation of Processors. https://amcc.alabama.gov/rules/
- Journal of the American Medical Association (JAMA). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. https://pubmed.ncbi.nlm.nih.gov/26103030/
- Alabama Board of Medical Examiners. Rule 540-X-25-.11: Dosage Limitations. https://admincode.legislature.state.al.us/
